136 related articles for article (PubMed ID: 36754037)
1. Impact of Geriatric Assessment on the Tolerability of Combination Chemotherapy in Older Patients with Advanced Cancer: A Matched-Pair Analysis.
Stahl MK; Ertl SW; Engelmeyer P; Heuer HC; Christoph DC
Oncol Res Treat; 2023; 46(3):100-105. PubMed ID: 36754037
[TBL] [Abstract][Full Text] [Related]
2. Prospective clinical trial evaluating vulnerability and chemotherapy risk using geriatric assessment tools in older patients with lung cancer.
Tsubata Y; Shiratsuki Y; Okuno T; Tanino A; Nakao M; Amano Y; Hotta T; Hamaguchi M; Okimoto T; Hamaguchi S; Kurimoto N; Nishiyama Y; Kimura T; Iwata H; Tsumoto S; Isobe T
Geriatr Gerontol Int; 2019 Nov; 19(11):1108-1111. PubMed ID: 31746525
[TBL] [Abstract][Full Text] [Related]
3. Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial.
Winther SB; Liposits G; Skuladottir H; Hofsli E; Shah CH; Poulsen LØ; Ryg J; Osterlund P; Berglund Å; Qvortrup C; Glimelius B; Sorbye H; Pfeiffer P
Lancet Gastroenterol Hepatol; 2019 May; 4(5):376-388. PubMed ID: 30852136
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy versus best supportive care for extensive small cell lung cancer.
Pelayo Alvarez M; Westeel V; Cortés-Jofré M; Bonfill Cosp X
Cochrane Database Syst Rev; 2013 Nov; (11):CD001990. PubMed ID: 24282143
[TBL] [Abstract][Full Text] [Related]
5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
6. Prospective Validation of The Korean Cancer Study Group Geriatric Score (KG)-7, a Novel Geriatric Screening Tool, in Older Patients with Advanced Cancer Undergoing First-line Palliative Chemotherapy.
Kim JW; Kim SH; Lee YG; Hwang IG; Kim JY; Koh SJ; Ko YH; Shin SH; Woo IS; Hong S; Kim TY; Baek JY; Kim HJ; Kim HJ; Lee MA; Kwon JH; Hong YS; Ryoo HM; Lee KH; Kim JH
Cancer Res Treat; 2019 Jul; 51(3):1249-1256. PubMed ID: 30653746
[TBL] [Abstract][Full Text] [Related]
7. Geriatric assessment in clinical practice for patients with stage IV non-small-cell lung cancer: The Grup de Investigació I Divulgació Oncològica experience.
Gironés R; Aparisi F; García-Sánchez J; Sánchez-Hernández A; García Piñón F; Juan-Vidal Ó
Eur J Cancer Care (Engl); 2018 Nov; 27(6):e12950. PubMed ID: 30357951
[TBL] [Abstract][Full Text] [Related]
8. Analysis of factors affecting progression-free survival of first-line chemotherapy in older patients with advanced gastrointestinal cancer.
Nakazawa J; Kawahira M; Kawahira M; Kodama T; Arima S; Iwashita Y; Mawatari S; Hashimoto S; Kanmura S; Hori T; Tsubouchi H; Ido A
J Geriatr Oncol; 2021 Nov; 12(8):1200-1207. PubMed ID: 33994149
[TBL] [Abstract][Full Text] [Related]
9. Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622).
Feliciano JL; Le-Rademacher JG; Gajra A; Edelman MJ; Zemla T; McMurray R; Chen H; Hurria A; Muss H; Cohen HJ; Lilenbaum R; Jatoi A
J Geriatr Oncol; 2018 Sep; 9(5):501-506. PubMed ID: 29848457
[TBL] [Abstract][Full Text] [Related]
10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
11. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
West H; McCleod M; Hussein M; Morabito A; Rittmeyer A; Conter HJ; Kopp HG; Daniel D; McCune S; Mekhail T; Zer A; Reinmuth N; Sadiq A; Sandler A; Lin W; Ochi Lohmann T; Archer V; Wang L; Kowanetz M; Cappuzzo F
Lancet Oncol; 2019 Jul; 20(7):924-937. PubMed ID: 31122901
[TBL] [Abstract][Full Text] [Related]
12. Sequential Geriatric Assessment in Older Patients with Colorectal Cancer during Chemotherapy: Subgroup Analysis of a Prospective, Multicenter Study EpiReal 75.
Li M; Schulte N; Elting F; Winkler EC; Hetjens S; Berger AK; Zschäbitz S; Hofmann J; Hofmann J; Hilbertz L; Kuhn M; Khakzar C; Jesenofsky R; Betge J; Zhan T; Belle S; Ebert MP; Härtel N
Oncol Res Treat; 2022; 45(11):670-680. PubMed ID: 35675788
[TBL] [Abstract][Full Text] [Related]
13. The relevance of geriatric assessment for older patients receiving palliative chemotherapy.
van der Vlies E; Kurk SA; Roodhart JML; Gerritse FL; Pelgrim TC; Vos JM; Sohne M; Hunting CB; Noordzij PG; van der Velden AMT; Los M
J Geriatr Oncol; 2020 Apr; 11(3):482-487. PubMed ID: 31160210
[TBL] [Abstract][Full Text] [Related]
14. Frailty assessment predicts toxicity during first cycle chemotherapy for advanced lung cancer regardless of chronologic age.
Ruiz J; Miller AA; Tooze JA; Crane S; Petty WJ; Gajra A; Klepin HD
J Geriatr Oncol; 2019 Jan; 10(1):48-54. PubMed ID: 30005982
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE
Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837
[TBL] [Abstract][Full Text] [Related]
16. Time-to-Treatment-Failure and Related Outcomes Among 1000+ Advanced Non-Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients (Alliance A151711).
Gajra A; Zemla TJ; Jatoi A; Feliciano JL; Wong ML; Chen H; Maggiore R; McMurray RP; Hurria A; Muss HB; Cohen HJ; Lafky J; Edelman MJ; Lilenbaum R; Le-Rademacher JG
J Thorac Oncol; 2018 Jul; 13(7):996-1003. PubMed ID: 29608967
[TBL] [Abstract][Full Text] [Related]
17. Comparison between single-agent and combination chemotherapy as second-line treatment for advanced non-small cell lung cancer: a multi-institutional retrospective analysis.
Yi Y; Liu Z; Fang L; Li J; Liu W; Wang F; Fu P; Xie C; Liu J; Song B
Cancer Chemother Pharmacol; 2020 Jul; 86(1):65-74. PubMed ID: 32533335
[TBL] [Abstract][Full Text] [Related]
18. Geriatric assessment is associated with completion of chemotherapy, toxicity, and survival in older adults with cancer.
Wildes TM; Ruwe AP; Fournier C; Gao F; Carson KR; Piccirillo JF; Tan B; Colditz GA
J Geriatr Oncol; 2013 Jul; 4(3):227-34. PubMed ID: 23795224
[TBL] [Abstract][Full Text] [Related]
19. Prediction of treatment-related toxicity and outcome with geriatric assessment in elderly patients with solid malignancies treated with chemotherapy: a systematic review.
Versteeg KS; Konings IR; Lagaay AM; van de Loosdrecht AA; Verheul HMW
Ann Oncol; 2014 Oct; 25(10):1914-1918. PubMed ID: 24569912
[TBL] [Abstract][Full Text] [Related]
20. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
